Table 1.
Differences in clinical and laboratory characteristics between T2-high and T2-low asthmatic patients.
| T2-low Asthma | T2-High Asthma | p Value b | |
|---|---|---|---|
| No. | 12 | 24 | |
| Age in years, median (IQR) | 59 (27.0) | 53 (19.3) | 0.779 |
| Female sex, No. (%) | 9 (75) | 17 (71) | 1.000 |
| BMI (kg/m2), median (IQR) | 25.2 (4.9) | 27.5 (5.7) | 0.748 |
| FEV1 (%) preBD, median (IQR) | 92.5 (39.3) | 70 (28.3) | 0.051 |
| FEV1 (L) preBD, median (IQR) | 2.43 (0.92) | 2.20 (1.02) | 0.366 |
| FEV1 (%) postBD, median (IQR) | 97 (38) | 77 (25) | 0.019 |
| FEV1 (L) postBD, median (IQR) | 2.99 (1.41) | 2.21 (1.31) | 0.050 |
| FEV1 (%) increase postBD, median (IQR) | 9 (16) | 7 (15.5) | 0.391 |
| Positive reversibility test, No. (%) | 2 (17) | 4 (17) | 1.000 |
| FeNO (ppb), median (IQR) | 44 (57) | 55 (69) | 0.365 |
| Total serum IgE (kU/L), median (IQR) | 338 (871) | 136 (261) | 0.449 |
| Blood eosinophils (cells/μL), median (IQR) | 205 (253) | 535 (855) | 0.035 |
| Sputum eosinophils (%), median (IQR) | 5 (11.5) | 18 (42.0) | 0.017 |
| Active/ex-smokers, No. (%) | 1/3 (8.3/25.0) | 2/4 (8.3/16.7) | 0.700 |
| Exacerbations in the past year, No. (%) | 8 (67) | 15 (63) | 1.000 |
| ICS use, No. (%) | 10 (83) | 22 (92) | 0.588 |
| OCS maintenance use, No. (%) | 2 (17) | 12 (50) | 0.076 |
| Seasonal allergic rhinitis, No. (%) | 6 (50) | 8 (33) | 0.472 |
| Perennial allergic rhinitis, No. (%) | 6 (50) | 12 (50) | 1.000 |
| Biological therapy a, No. (%) | 1 (8) | 15 (63) | 0.004 |
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 s; FeNO, exhaled nitric oxide; ICS, inhaled corticosteroids; preBD, pre-bronchodilation; postBD, post-bronchodilation; OCS, oral corticosteroids. a Omalizumab (eight patients) or Mepolizumab (eight patients). b Statistically significant p values are in boldface.